Drug-Induced Nodular Regenerative Hyperplasia

 

 Buy Article Permissions and Reprints

Abstract

Drug-induced nodular regenerative hyperplasia is an uncommon injury with unique pathophysiology, clinical, and diagnostic considerations. This injury is characteristically asymptomatic in its early phases with only mild elevations in transaminases (< 3× upper limit of normal [ULN]). The latency period is typically more than 6 months. Once clinically apparent, it is marked by complications of portal hypertension, including hypersplenism, ascites, and variceal bleeding, with little or no hepatic dysfunction. Hence, it is an important cause of noncirrhotic portal hypertension. The most commonly associated drugs include thiopurines, chemotherapeutic agents, and antiretroviral agents. Diagnosis is aided by the recognition of noncirrhotic portal hypertension, a detailed history of prior drug exposure, and exclusion of the other causes of nodular regenerative hyperplasia. Clinical history, abdominal imaging, and hepatic hemodynamic studies provide important diagnostic clues, but histologic examination remains the diagnostic gold standard. Therapeutic intervention is aimed at earliest discontinuation of the offending agent and of portal hypertension complications. The natural history varies widely, and portal hypertension can progresses despite drug discontinuation.

• References

• 1 Chalasani N, Fontana RJ, Bonkovsky HL , et al; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135 (6) 1924-1934 , e1–e4
  CrossrefPubMedGoogle Scholar
• 2 Kleiner DE, Chalasani NP, Lee WM , et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59 (2) 661-670
  CrossrefPubMedGoogle Scholar
• 3 Steiner PE. Nodular regenerative hyperplasia of the liver. Am J Pathol 1959; 35: 943-953
  PubMedGoogle Scholar
• 4 Dachman AH, Ros PR, Goodman ZD, Olmsted WW, Ishak KG. Nodular regenerative hyperplasia of the liver: clinical and radiologic observations. AJR Am J Roentgenol 1987; 148 (4) 717-722
  CrossrefPubMedGoogle Scholar
• 5 Ranstrom S. Miliary hepatocellular adenomatosis. Acta Pathol Microbiol Scand 1953; 33 (3) 225-229
  PubMedGoogle Scholar
• 6 Rothweiler S, Terracciano L, Tornillo L, Dill MT, Heim MH, Semela D. Downregulation of the Endothelial Genes Notch1 and EphrinB2 in Patients with Nodular Regenerative Hyperplasia. Liver Int 2014; 34 (4) 594-603
  CrossrefPubMedGoogle Scholar
• 7 Rothweiler S, Heim MH, Semela D. Nodular regenerative hyperplasia in a patient with generalized essential telangiectasia: Endotheliopathy as causal factor. Hepatology 2013;
  PubMedGoogle Scholar
• 8 Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11 (5) 787-797
  CrossrefPubMedGoogle Scholar
• 9 Hartleb M, Gutkowski K, Milkiewicz P. Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension. World J Gastroenterol 2011; 17 (11) 1400-1409
  CrossrefPubMedGoogle Scholar
• 10 Morris JM, Oien KA, McMahon M , et al. Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. Eur J Gastroenterol Hepatol 2010; 22 (8) 1001-1005
  CrossrefPubMedGoogle Scholar
• 11 Bissonnette J, Généreux A, Côté J , et al. Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. J Gastroenterol Hepatol 2012; 27 (8) 1336-1340
  CrossrefPubMedGoogle Scholar
• 12 Musumba CO. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy. Aliment Pharmacol Ther 2013; 38 (9) 1025-1037
  CrossrefPubMedGoogle Scholar
• 13 De Boer NK, Tuynman H, Bloemena E , et al. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand J Gastroenterol 2008; 43 (5) 604-608
  CrossrefPubMedGoogle Scholar
• 14 Cotte L, Bénet T, Billioud C , et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol 2011; 54 (3) 489-496
  CrossrefPubMedGoogle Scholar
• 15 Hubert C, Sempoux C, Horsmans Y , et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?. Liver Int 2007; 27 (7) 938-943
  CrossrefPubMedGoogle Scholar
• 16 Nguyen-Khac E, Lobry C, Chatelain D , et al. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol 2013; 2013: 314868
  PubMedGoogle Scholar
• 17 Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12 (1) 94-99
  CrossrefPubMedGoogle Scholar
• 18 Wicherts DA, de Haas RJ, Sebagh M , et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 2011; 18 (3) 659-669
  CrossrefPubMedGoogle Scholar
• 19 Force Sr J, Schneider B, Storniolo A, Sledge GW, Chalasani N, Vuppalanchi R. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. J Clin Oncol 2014; ; [Epub ahead of print]
  PubMedGoogle Scholar
• 20 Caturelli E, Ghittoni G, Ranalli TV, Gomes VV. Nodular regenerative hyperplasia of the liver: coral atoll-like lesions on ultrasound are characteristic in predisposed patients. Br J Radiol 2011; 84 (1003) e129-e134
  CrossrefPubMedGoogle Scholar
• 21 Siegelman ES, Outwater EK, Furth EE, Rubin R. MR imaging of hepatic nodular regenerative hyperplasia. J Magn Reson Imaging 1995; 5 (6) 730-732
  CrossrefPubMedGoogle Scholar
• 22 Ames JT, Federle MP, Chopra K. Distinguishing clinical and imaging features of nodular regenerative hyperplasia and large regenerative nodules of the liver. Clin Radiol 2009; 64 (12) 1190-1195
  CrossrefPubMedGoogle Scholar
• 23 Hofmaenner D, Kovari H, Weber A, Weishaupt D, Speck RF. Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption. BMJ Case Rep 2011; 2011
  PubMedGoogle Scholar
• 24 Duseja A, Chawla Y. Portal hypertension in nodular regenerative hyperplasia: a mixed bag!. J Gastroenterol Hepatol 2012; 27 (8) 1260-1262
  CrossrefPubMedGoogle Scholar
• 25 Laharie D, Vergniol J, Bioulac-Sage P , et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010; 22 (4) 487-493
  CrossrefPubMedGoogle Scholar
• 26 Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20 (1 Pt 1) 88-94
  CrossrefPubMedGoogle Scholar
• 27 Ranucci G, Cirillo F, Della Corte C, Vecchione R, Vallone G, Iorio R. Successful use of ursodeoxycholic acid in nodular regenerative hyperplasia of the liver. Ann Pharmacother 2011; 45 (4) e20
  CrossrefPubMedGoogle Scholar
• 28 Bihl F, Janssens F, Boehlen F, Rubbia-Brandt L, Hadengue A, Spahr L. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol 2010; 10: 6
  CrossrefPubMedGoogle Scholar
• 29 Louwers LM, Bortman J, Koffron A, Stecevic V, Cohn S, Raofi V. Noncirrhotic Portal Hypertension due to Nodular Regenerative Hyperplasia Treated with Surgical Portacaval Shunt. Case Rep Med 2012; 2012: 965304
  PubMedGoogle Scholar
• 30 Manzia TM, Gravante G, Di Paolo D , et al. Liver transplantation for the treatment of nodular regenerative hyperplasia. Dig Liver Dis 2011; 43 (12) 929-934
  CrossrefPubMedGoogle Scholar
• 31 Al-Hamoudi WK, Pasieka JL, Urbanski SJ, Lee SS. Hepatic nodular regenerative hyperplasia in a patient with advanced carcinoid tumor. Eur J Gastroenterol Hepatol 2009; 21 (9) 1083-1085
  CrossrefPubMedGoogle Scholar
• 32 Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004; 75 (4) 225-230
  CrossrefPubMedGoogle Scholar
• 33 Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44 (1) 7-14
  CrossrefPubMedGoogle Scholar
• 34 Podevin P, Spiridon G, Terris B , et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20 (2) 313-315
  CrossrefPubMedGoogle Scholar
• 35 Beer TW, Carr NJ, Buxton PJ. Thorotrast associated nodular regenerative hyperplasia of the liver. J Clin Pathol 1998; 51 (12) 941-942
  CrossrefPubMedGoogle Scholar
• 36 Rubbia-Brandt L, Lauwers GY, Wang H , et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56 (4) 430-439
  CrossrefPubMedGoogle Scholar
• 37 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19 (13) 4287-4299
  CrossrefPubMedGoogle Scholar
• 38 Scourfield A, Waters L, Holmes P , et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS 2011; 22 (6) 324-328
  CrossrefPubMedGoogle Scholar
• 39 Schiff ER, Sorrell MF, Maddrey WC , eds. Schiff's diseases of the liver. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2003: 1152-1155
  Google Scholar